EchoIQ has moved beyond the familiar medtech pitch of promising smarter healthcare someday. It now sits at a more demanding stage: proving that its cardiac AI can fit real hospital workflows, support clinicians, and scale across the United States. Hospitals rarely adopt new software because an algorithm sounds impressive; they adopt tools that save time, improve consistency, and fit into existing routines without causing chaos. EchoIQ targets that practical gap with measurement-based decision support drawn from routine echocardiograms. Recent partnerships, clinical collaborations, and access to a larger imaging dataset have widened the company’s opportunity while raising execution expectations. The chart mirrors that transition: strong momentum, a pullback, and a test of support inside a rising structure. Investors now need to watch delivery, not just ambition.

What Does EchoIQ (ASX: EIQ) Do?

EchoIQ develops artificial intelligence software that helps clinicians assess structural heart disease from measurements clinicians already capture during echocardiograms. Its platform, EchoSolv, analyses numerical echo data rather than interpreting raw ultrasound images. That approach lets hospitals add decision support without replacing existing scanners or asking clinicians to change the exam.

The company’s lead commercial product, EchoSolv AS, estimates the probability of severe aortic stenosis and checks routine measurements against clinical guidelines. The US Food and Drug Administration cleared EchoSolv AS through the 510(k) pathway in October 2024. EchoIQ also develops EchoSolv HF, a heart-failure decision-support product.

EchoIQ aims to help cardiology teams find overlooked cases, review studies more consistently, and prioritise patients who need closer assessment. Clinicians keep final responsibility for diagnosis and treatment decisions in every clinical setting.

Our most recent analysis of EchoIQ (ASX: EIQ) is available here.

EchoIQ (ASX: EIQ) Recent Updates & Projects

EIQ spent the first half of 2026 building the capital, data, clinical evidence, and distribution channels needed for a broader US commercial push.

Funding and Pro Medicus Partnership

On 1 July, EchoIQ announced an A$110 million institutional placement. Management plans to use the funds for US expansion, product development, infrastructure, regulatory work, and working capital. Days earlier, the company signed a binding heads of agreement with Pro Medicus. Pro Medicus agreed to invest an initial A$10 million through secured convertible notes and may add another A$10 million after FDA clearance for EchoSolv HF. The proposed reseller arrangement gives EchoIQ access to Pro Medicus’ US healthcare network.

Exclusive Data Licence Expands the Moat

EchoIQ also secured exclusive access to between 500,000 and one million de-identified echocardiography studies from Advara HeartCare. Advara guarantees at least 500,000 studies, subject to ethics approval and quality checks. EchoIQ will retain ownership of AI outputs. The three-year agreement includes a three-year extension option and supports training, validation, and future multi-condition products.

Mayo Clinic Research and Hospital Deployment

EchoIQ expanded its relationship with the Mayo Clinic on two fronts. Mayo Clinic can resell and distribute EchoSolv HF after FDA clearance, while a separate Arizona study will test cardiac-risk scoring in cancer patients and target publication in early 2027. EchoIQ also placed EchoSolv AS inside Mount Sinai Health System, which spans seven hospitals and more than 400 outpatient practices. These projects test whether the software can move from clinical promise into routine use. Investors should track contract conversion, reimbursement progress, regulatory timing, and evidence that deployments generate recurring commercial revenue.

Important Disclaimer: You’re reading a free article that offers general opinions and insights. For exclusive, in-depth research, timely high-conviction investment ideas, and actionable trade signals designed to help you stay ahead, join Proactive Equities today by opening a Free Trial Account now! (No Credit Card Required)

Technical Analysis of EchoIQ (ASX: EIQ)

Source: TradingView

EchoIQ’s daily chart still shows a rising channel, but the latest candles have pulled back toward a decisive support zone. The setup remains constructive while buyers defend that area; a clean break would weaken the pattern.

Risk management matters because the spread between support and the second target appears attractive. Yet small-cap medtech shares can gap sharply around regulatory announcements, placements, or commercial news in either direction without warning.

Primary support: A$1.35–A$1.40. This band matches the blue horizontal level and the lower part of the recent consolidation. Buyers need a daily close above it to preserve the bullish structure.

Resistance and First target: A$1.80–A$1.85. The orange zone marks the recent rejection area. A breakout needs stronger volume, and a firm daily close above $1.85.

Upside target: $2.85–$3.05. This region aligns with the chart’s second target and the upper half of the rising channel.

Stop-loss approach: Our stop-loss sits just under both the support zone and the ascending channel base. A period of consolidation that resolves with a break lower would invalidate the bullish case and likely initiate a medium-term bearish trend.

Momentum: RSI sits near 46, which signals neutral-to-soft momentum rather than an oversold condition. Volume expanded during the late-June surge, then eased during the pullback. That pattern supports consolidation, but buyers still need confirmation. A rebound from support followed by a higher low would strengthen the setup. A close below the channel would cancel the bullish thesis and shift attention to capital protection.

FAQs about EchoIQ (ASX: EIQ)

1. How does EchoIQ differ from AI software that reads ultrasound images?

EchoIQ analyses measurements that clinicians already collect during an echocardiogram. It does not interpret raw images. EchoSolv AS combines those measurements with its AI model and guideline checks to produce a probability assessment of severe aortic stenosis.

2. What could delay EchoIQ’s commercial rollout?

FDA review could delay EchoSolv HF, while hospital procurement, reimbursement, workflow integration, and contract conversion could slow adoption. EchoIQ also needs its software to perform reliably across large clinical networks and turn deployments into sustainable revenue.

3. Could EchoIQ expand beyond aortic stenosis and heart failure?

Yes, research must support each new application. The Mayo Clinic Arizona project will assess cardiac-risk scoring among cancer patients, while the Advara dataset may help EchoIQ develop broader cardiovascular products.